Concepedia

Author

Helen Meadows

University College London

Also Known As

Alison M. McDonald, H M Meadows, H Meadows, H. M. Meadows, H. Meadows, H.M. Meadows, H.M.d.C.A.J. Meadows, Helen M Meadows, Helen M. Meadows, Helen Margaret Meadows

47

Publications

3.4K

Citations

23

H-Index

43

Concepts

All Affiliations

University College LondonCancer Research UKSt James's University HospitalMount Vernon HospitalRoyal Marsden Hospital
HM

About

Helen Meadows is an author at University College London specializing in medicine, oncology, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

17

19

2.4K

2

Health Sciences

8

8

966

3

Natural Sciences

1

1

29

4

Biology

1

1

20

5

Cell Biology

1

1

26

Helen Meadows

×

24

Publications

3.3K

Citations

21

H-Index

YearCitations

Epidermoid anal cancer: Results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin

S.J. Arnott, David Cunningham, James Gallagher,

Oxford University Research Archive (ORA) (University of Oxford)

1996

727

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2×2 factorial trial

R.D. James, Rob Glynne‐Jones, Helen Meadows,

The Lancet Oncology

2013

711

Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR Anal Cancer Trial (ACT I)

John Northover, Rob Glynne‐Jones, David Sebag‐Montefiore,

British Journal of Cancer

2010

422

Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control

Rob Glynne‐Jones, Nicholas Counsell, Philip Quirke,

Annals of Oncology

2014

290

Best time to assess complete clinical response after chemoradiotherapy in squamous cell carcinoma of the anus (ACT II): a post-hoc analysis of randomised controlled phase 3 trial

Rob Glynne‐Jones, David Sebag‐Montefiore, Helen Meadows,

The Lancet Oncology

2017

178

EXTRA—A Multicenter Phase II Study of Chemoradiation Using a 5 Day per Week Oral Regimen of Capecitabine and Intravenous Mitomycin C in Anal Cancer

Rob Glynne‐Jones, Helen Meadows, Susan Wan,

International Journal of Radiation Oncology*Biology*Physics

2008

144

A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study

David Sebag‐Montefiore, Rob Glynne‐Jones, S. Falk,

British Journal of Cancer

2005

93

Prognostic factors for recurrence and survival in anal cancer

Rob Glynne‐Jones, David Sebag‐Montefiore, Richard Adams,

Cancer

2012

90

A randomized trial of chemoradiation using mitomycin or cisplatin, with or without maintenance cisplatin/5FU in squamous cell carcinoma of the anus (ACT II)

Rebecca James, Shanshan Wan, R. Glynne‐Jones,

Journal of Clinical Oncology

2009

81

“Mind the Gap”—The Impact of Variations in the Duration of the Treatment Gap and Overall Treatment Time in the First UK Anal Cancer Trial (ACT I)

Rob Glynne‐Jones, David Sebag‐Montefiore, Richard Adams,

International Journal of Radiation Oncology*Biology*Physics

2010

63

Page 1